Fred Hutchinson Cancer Center

This early-phase study tests a personalized vaccine made from unique markers on a patient's own tumor. The goal is to help the immune system fight advanced breast cancer, melanoma, and lung cancer that has not responded to other treatments. About 25 adults with these cancers will…

This study tests a new treatment sequence for adults with aggressive blood cancers (like AML, MDS, or CMML) that are likely to return after standard therapy. Participants receive a combination of chemotherapy drugs (decitabine plus FLAG-Ida) followed by low-dose radiation and a d…

This early-phase trial tests a personalized cell therapy for people with metastatic solid tumors that have a specific genetic change called KRAS G12V. The patient's own immune cells are collected, genetically modified to recognize and attack the cancer, and then infused back. The…

This early-stage study tests a new treatment for children and adults whose acute leukemia has come back or not responded after a donor stem cell transplant. The treatment uses specially engineered immune cells (T cells) from the original donor that are trained to recognize and at…

This study tests whether reducing the dose of the drug linvoseltamab after an initial response can keep multiple myeloma under control while causing fewer side effects. About 30 adults with relapsed or treatment-resistant myeloma will receive a lower dose based on their individua…

This study tests a treatment plan for adults aged 60 and older with newly diagnosed, high-risk acute myeloid leukemia (AML) or similar blood cancers. The plan combines strong chemotherapy (FLAG-Ida) with a donor stem cell transplant shortly after, aiming to shorten the dangerous …

This study tests a new mix of two drugs (pralatrexate and bendamustine) plus low-dose total-body radiation before a donor stem cell transplant for people with T-cell lymphoma that has returned or not responded to treatment. The goal is to safely prepare the body for the transplan…

This study tests whether giving antibody replacements can prevent serious infections in people who have received CAR-T therapy for blood cancers. CAR-T therapy often lowers the body's natural antibodies, raising infection risk. The trial will compare antibody replacement to a pla…

This study tests whether patient navigation services, an interactive website, or both can help people who had stage I-III colorectal cancer get the follow-up tests their doctors recommend. About 75 survivors will be assigned to one of three groups to see which approach works best…